Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:171 |
Name | neuroectodermal tumor |
Definition | |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer nervous system cancer neuroectodermal tumor |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
ALK over exp | Crizotinib | neuroectodermal tumor | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00983398 | Phase Ib/II | Pegfilgrastim Filgrastim Carboplatin + Melphalan | Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors | Unknown status | USA | 0 |
NCT03155620 | Phase II | Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | Recruiting | USA | CAN | AUS | 1 |
NCT03210714 | Phase II | Erdafitinib | Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03698994 | Phase II | Ulixertinib | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03911388 | Phase I | HSV-1 G207 | HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors | Active, not recruiting | USA | 0 |
NCT04129151 | Phase II | Ganitumab + Palbociclib | Palbociclib + Ganitumab In Ewing Sarcoma | Terminated | USA | 0 |
NCT04541082 | Phase I | ONC206 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | Recruiting | USA | 0 |
NCT04661852 | Phase I | Cabozantinib + Cyclophosphamide + Pegfilgrastim + Topotecan Cabozantinib + Cyclophosphamide + Filgrastim + Topotecan | Cabozantinib With Topotecan-Cyclophosphamide | Completed | USA | 0 |
NCT05106296 | Phase I | Cyclophosphamide + Etoposide + Ibrutinib + Indoximod | Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer | Recruiting | USA | 0 |
NCT05887882 | Phase I | TGF-beta-imprinted NK cells | Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Brain Tumors (PNOC028) | Recruiting | USA | 0 |
NCT06638931 | Phase II | Nivolumab | Agnostic Therapy in Rare Solid Tumors (ANTARES) | Recruiting | BRA | 0 |